Abaloparatide (Tymlos) coverage
Customize your policy alerts
Sign up for QualChoice Policy CP.PCH.61 alerts
Get alerted when Policy CP.PCH.61 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization criteria for abaloparatide (Tymlos) for treatment of osteoporosis in postmenopausal women and men at high fracture risk, and continuation criteria for members under QualChoice lines of business.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.